Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Designing comprehensive and impactful implementation strategies for cancer-associated thrombosis prevention
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Despite strong evidence and professional society recommendations for interventions to reduce cancer-associated thrombosis, uptake in clinical practice remains low. Implementation science offers structured approaches to close this evidence-to-practice gap. Frameworks such as the Implementation Research Logic Model and Consolidated Framework for Implementation Research guide identification of barriers, selection of strategies to address the barriers, and evaluation of clinical and implementation outcomes. Herein, the application of implementation science to close the gap between evidence for cancer-associated thrombosis prevention and use in clinical practice is discussed. Multi-level strategies, including clinician and patient education and electronic health record decision support, are essential to improve adoption. Clinical programs such as the Vermont Model demonstrate feasibility but highlight challenges in sustainability and scale-up. Integrating recommended cancer-associated prevention interventions into routine oncology care through tailored implementation strategies can reduce preventable morbidity and mortality, improving outcomes for patients with cancer.
Downloads
Download data is not yet available.
Citations
1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4. DOI: https://doi.org/10.1111/j.1538-7836.2007.02374.x
2. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. DOI: https://doi.org/10.1182/blood-2007-10-116327
3. Martin KA, Holmes C. Time to move beyond risk assessment models for ambulatory cancer-associated thrombosis. Res Pract Thromb Haemost 2025;9:102991. DOI: https://doi.org/10.1016/j.rpth.2025.102991
4. Rutjes AW, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2020;12:CD008500. DOI: https://doi.org/10.1002/14651858.CD008500.pub5
5. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380:711-9. DOI: https://doi.org/10.1056/NEJMoa1814468
6. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720-8. DOI: https://doi.org/10.1056/NEJMoa1814630
7. Bosch FTM, Mulder FI, Kamphuisen PW, et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 2020;4:5215-25. DOI: https://doi.org/10.1182/bloodadvances.2020003115
8. Khorana AA, Otten H-M, Zwicker JI, et al. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost 2014;12:1928-31. DOI: https://doi.org/10.1111/jth.12725
9. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496-520. DOI: https://doi.org/10.1200/JCO.19.01461
10. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74. DOI: https://doi.org/10.1182/bloodadvances.2021004734
11. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23:e334-47.
12. Kakkar AK, Levine M, Pinedo HM, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381-8. DOI: https://doi.org/10.1634/theoncologist.8-4-381
13. Martin KA, Molsberry R, Khan SS, et al. Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis. Res Pract Thromb Haemost 2020;4:1211-5. DOI: https://doi.org/10.1002/rth2.12431
14. Holmes CE, Ades S, Gilchrist S, et al. Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. JCO Oncol Pract 2020;16:e868-74. DOI: https://doi.org/10.1200/JOP.19.00697
15. Association of Community Cancer Centers [Internet]. Venous thromboembolism. Identifying cancer patients at risk. 2016. Accessed: 2022 Oct 19. Available from: https://www.accc-cancer.org/docs/projects/resources/pdf/vte-identifying-cancer-patients-at-risk-2016
16. Smith JD, Li DH, Rafferty MR. The implementation research logic model: a method for planning, executing, reporting, and synthesizing implementation projects. Implement Sci 2020;15:84. DOI: https://doi.org/10.1186/s13012-020-01041-8
17. Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci 2022;17:75. DOI: https://doi.org/10.1186/s13012-022-01245-0
18. Martin KA, Lyleroehr MJ, Cameron KA. Barriers and facilitators to preventing venous thromboembolism in oncology practice. Thromb Res 2022;220:21-3. DOI: https://doi.org/10.1016/j.thromres.2022.09.026
19. Lustig DB, Rodriguez R, Wells PS. Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thromb Res 2015;136:1099-102. DOI: https://doi.org/10.1016/j.thromres.2015.08.002
20. Kunapareddy G, Switzer B, Jain P, et al. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. Res Pract Thromb Haemost 2019;3:226-33. DOI: https://doi.org/10.1002/rth2.12176
21. Gramaça J, Lopes AR, Ganhão M, et al. Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting. Thromb Update 2024;16:100187. DOI: https://doi.org/10.1016/j.tru.2024.100187
22. Ades S, Resnick Y, Barker J, et al. Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study. Lancet Reg Health Am 2024;38:100866. DOI: https://doi.org/10.1016/j.lana.2024.100866
23. Feldman HM, Tipirneni E, Khan S, et al. Implementation of a cancer-associated thrombosis prevention program at a rural cancer center. Res Pract Thromb Haemost 2023;8:102286. DOI: https://doi.org/10.1016/j.rpth.2023.102286
CRediT authorship contribution
KAM, study concept, data analysis and interpretation, manuscript original drafting and editing.
Supporting Agencies
National Heart, Lung, and Blood Institute, National Institutes of Health, BethesdaHow to Cite
1.
Martin KA. Designing comprehensive and impactful implementation strategies for cancer-associated thrombosis prevention. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/454
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
